The ultimate goal of this proposal is to develop a technology platform for the rapid, robust single molecule analysis of extracellular RNA (exRNA) biomarkers for cancer detection. ExRNAs are blood- or urine-borne, cell-free, both short and long non-coding RNAs released from cells through apoptosis or possibly as external signaling molecules. Many of them are stable in human biofluids over days, rendering them of high interest as clinical biomarkers in disease diagnosis and epidemiology. Procedural, assay, and study cohort heterogeneity has led to both false-positive and false-negative exRNA-cancer associations, hampering clinical application. We recently developed an innovative technology, termed SiMREPS, for the direct single-molecule identification and counting of exRNAs in crude biofluids without the need for either amplification or labeling, overcoming many of the current challenges in biomarker detection. We propose to critically advance SiMREPS by incorporating multiplexing.
$413,333 grant from the National Cancer Institute.
$620,000 grant from the National Cancer Institute
A high-specificity, direct single molecule counting technology to enable cell-free DNA-based liquid biopsy for oncology
$200,000 grant from Fast Forward Medical Innovation, MTRAC, University of Michigan
A Novel Single Molecule Counting Technology Enabling Non-Invasive Detection and Monitoring of Cancer via Trans-Renal Circulating Tumor DNA in Urine
$50,000 grant from the Comprehensive Cancer Center, University of Michigan
$50,000 grant from Fast Forward Medical Innovation, University of Michigan
Published in Nature Biotechnology, 2015
Published in the Journal of the American Chemical Society, 2018